Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US81663L2007
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00XDHY5P9
WGS
GeneDx Holdings Corp
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $GRLZ
NAME
GeneDx Holdings Corp
ISIN
US81663L2007
TICKER
WGS
MIC
XNAS
REUTERS
WGS.OQ
BLOOMBERG
WGS US
Mi., 06.05.2026       GeneDx
US81663L2007

Boston, Massachusetts--(Newsfile Corp. - May 6, 2026) - Block & Leviton is investigating GeneDX Holdings Corp. (NASDAQ: WGS) for potential securities law violations. Investors who have lost money in their GeneDX Holdings Corp. investment should contact the firm to learn more about how they might recover those losses. For more details, visit htt...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mi., 06.05.2026       GeneDx
US81663L2007

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) investors concerning the Company’s possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON GENE...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mi., 06.05.2026       GeneDx
US81663L2007

Law Offices of Howard G. Smith announces an investigation on behalf of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GENEDX HOLDINGS CORP. (WGS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTEN...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 05.05.2026       GeneDx
US81663L2007

The Law Offices of Frank R. Cruz announces an investigation of GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON GENEDX HOLDINGS CORP. (WGS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM T...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 05.05.2026       GeneDx
US81663L2007

MILWAUKEE, May 5, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against GeneDx (Nasdaq: WGS). The investigation results from inaccurate statements GeneDx may have made regarding its financial statements, business operations and prospects....
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mo., 04.05.2026       GeneDx
US81663L2007

GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the first quarter of 2026. “GeneDx delivered 34% year-over-year volume growth in exome and genome testing in the first quarter – a clear signal that there’s sustained, strong d...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mo., 13.04.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the first quarter of 2026 after the market closes on Monday, May 4, 2026. Management will host a conference call that day to discuss first quarter 2026 financial and operating resu...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mi., 11.03.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced findings from the Genetic Sequencing Analysis has Value in Economic Savings (SAVES)-Kids Study, a real-world data Health Economics and Outcomes Research (HEOR) analysis led by GeneDx that focuses on the economic impact...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 10.03.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-P...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced scientific contributions to be presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Meeting. GeneDx will present 18 accepted abstracts, including three platform presentations and two ra...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 26.02.2026       GeneDx
US81663L2007

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders....
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mi., 25.02.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences: TD Cowen 46th Annual Health Care Conference Boston, MA Fireside Chat: Monday, March 2 at 1:50 p.m. ET Barclays 28th Annual Global H...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mo., 23.02.2026       GeneDx
US81663L2007

Insert the "Software and interpretation services" row in the Volume & Revenue(1) table. The updated release reads: GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026 GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mo., 23.02.2026       GeneDx
US81663L2007

GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the fourth quarter and full year of 2025. “The unmet need for early, accurate genomic diagnosis is enormous, and families are waiting far too long for answers. GeneDx is unique...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mi., 11.02.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its President and Chief Executive Officer Katherine Stueland has been named to the TIME100 Health 2026 list – TIME’s annual recognition of the 100 individuals who most influenced global health over the past year....
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 03.02.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the fourth quarter of 2025 before the market opens on Monday, February 23, 2026. Management will host a conference call that day to discuss fourth quarter 2025 financial and operating results at 8:30...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 15.01.2026       GeneDx
US81663L2007

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders. If you currently own GeneDx stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the com...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mo., 12.01.2026       GeneDx
US81663L2007

GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for the fourth quarter and full year of 2025. “In 2025, GeneDx continued its journey of transforming the standard of pediatric care by accelerating the use of genomics to the earliest moment...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 08.01.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, the leader in AI-powered healthcare intelligence. Through the partnership, GeneDx’s Infinity™ will leverage real-world patient insights from Komodo’s Healthcare Map®, to create the most compreh...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mi., 07.01.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced GenomeDx Prenatal™, whole genome sequencing (WGS) designed to deliver clear, reliable answers during one of the most critical moments in pregnancy care. The phenotype-informed, trio-based test is intended for pregnancies with fetal anoma...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 06.01.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights today announced Linda Genen, MD, MPH as Chief Medical Officer to further strengthen the company’s commitment to delivering earlier answers and better outcomes for families through genomic insights. This press release features multimedia. View the full r...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mo., 05.01.2026       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a record-setting year for its Medical Affairs and research programs, reinforcing its position as the global leader in rare disease genomics. In 2025, GeneDx published 79 peer-reviewed studies bringing its total to over 1,100 peer-reviewe...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 30.12.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15 in San Francisco, CA. Katherine Stueland, President and Chief Executive Officer, will participate in a presentation on Wedne...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mo., 15.12.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that the GUARDIAN (Genomic Uniform-screening Against Rare Disease In All Newborns) study has been recognized as part of JAMA’s annual Research of the Year Roundup. This highly selective honor is reserved for the most impactful scientific...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
So., 30.11.2025       GeneDx
US81663L2007

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Nov. 30, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders....
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 06.11.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting. “GeneDx is at the forefront of genomic discovery, accelerating gene-disease insights, advancing long-rea...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 04.11.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences: Stifel 2025 Healthcare Conference New York, New York Fireside Chat: Wednesday, November 12 at 2:00 p.m. ET Jefferies Global Healthcare Conference Lo...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 28.10.2025       GeneDx
US81663L2007

GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third quarter of 2025. “GeneDx’s accelerated growth reflects more than business momentum - it’s proof of the profound impact we’re making for families navigating rare disease and the broader...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mo., 27.10.2025       GeneDx
US81663L2007

SAN FRANCISCO, Oct. 27, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP reminds GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating to whether the company misled investors about its health intelligence platform called Centrellis. Current shareholder...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Fr., 24.10.2025       GeneDx
US81663L2007

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders. If you currently own GeneDx stock and acquired shares on or before January 18, 2022, you may be able to seek corporate governance reforms, the return of fun...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mi., 22.10.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced data and presentations at the International Consortium on Newborn Sequencing (ICoNS), underscoring the company’s leadership in driving genomic newborn screening (gNBS) from research into real-world clinical implementation. As the labor...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mo., 20.10.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its whole genome and exome tests associated with causes of life-threatening diseases or genetic disorders to aid in diagnosis of symptomatic...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 14.10.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Dr. Mimi Lee, MD, PhD, as Chief Precision Medicine Officer. Dr. Lee will spearhead GeneDx’s vision to unlock the power of genomics to help every person live their healthiest life. As Chief Precision Medicine Officer, Dr. Lee will lead...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mo., 13.10.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Florida State University has selected GeneDx as one of its partners for the recently passed Sunshine Genetics Act, a groundbreaking initiative establishing the nation’s first state-backed genomic newborn screening (gNBS) program. The S...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 09.10.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the Autism Partnership Program to expand access to its industry leading exome and genome testing – the only autism testing program committed to delivering answers to families in weeks. Jaguar Gene Therapy joins the program as the foundin...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mi., 08.10.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced pioneering scientific contributions that will be presented at the American Society of Human Genetics (ASHG) Annual Meeting. At ASHG, GeneDx will unveil research findings drawn from GeneDx Infinity™, a dataset of nearly one million exom...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 07.10.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the third quarter of 2025 before the market opens on Tuesday, October 28, 2025. Management will host a conference call that day to discuss third quarter 2025 financial and operating results at 8:30 a...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mi., 01.10.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, alongside Mass General Brigham, Ariadne Labs, Boston Children’s Hospital, Albert Einstein College of Medicine, the Association of Public Health Laboratories (APHL), Case Western Reserve University, Baylor College of Medicine, and Illumina, today announc...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 30.09.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Lisa Gurry as Chief Business Officer (CBO), effective immediately. In this newly-created role, Gurry will lead GeneDx’s next phase of transformation, advancing data and information services across biopharma, health sys...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 25.09.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will introduce pediatricians to GeneDx’s Infinity, the company’s proprietary dataset, at the American Academy of Pediatrics (AAP) National Conference & Exhibition taking place this weekend September 26 to 30 in Denver, CO. Infinit...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Do., 18.09.2025       GeneDx
US81663L2007

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Thomas Fuchs, Dr.sc., Chief AI Officer at Eli Lilly and Company, to its board of directors. “With the world’s largest rare disease data set, we’re only beginning to realize AI’s full potential to deliver faster, more...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
So., 31.08.2025       GeneDx
US81663L2007

NEW YORK, Aug. 31, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from al...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 26.08.2025       GeneDx
US81663L2007

NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from al...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 19.08.2025       GeneDx
US81663L2007

NEW YORK, Aug. 18, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from al...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mi., 13.08.2025       GeneDx
US81663L2007

NEW YORK, Aug. 13, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from al...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Fr., 08.08.2025       GeneDx
US81663L2007

NEW YORK, Aug. 8, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from all...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
So., 03.08.2025       GeneDx
US81663L2007

NEW YORK, Aug. 3, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from al...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 29.07.2025       GeneDx
US81663L2007

GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the second quarter of 2025. “Crossing the $100 million revenue mark and delivering our fourth consecutive profitable quarter is a major milestone for GeneDx, putting us on a path for more growth...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Di., 29.07.2025       GeneDx
US81663L2007

NEW YORK, July 28, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from al...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink
Mo., 28.07.2025       GeneDx
US81663L2007

LOS ANGELES, July 28, 2025 /PRNewswire/ -- News provided by DJS Law Group LLP The DJS Law Group reminds investors that it is investigating claims GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of securities laws.  The investigation centers on whether the Company made false and/or misleading statements or failed to...
Zur Nachricht
GeneDx
Charts & Research Termsheets Terminal
Permalink